​

MacroGenics (MGNX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

MGNX Stock Forecast

MacroGenics (MGNX) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $6.00, with a high of $6.00 and a low of $6.00. This represents a 41.51% increase from the last price of $4.24.

- $4 $8 $12 $16 $20 High: $6 Avg: $6 Low: $6 Last Closed Price: $4.24

MGNX Stock Rating

MacroGenics stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 12 Buy (54.55%), 9 Hold (40.91%), 1 Sell (4.55%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 1 9 12 Strong Sell Sell Hold Buy Strong Buy

MGNX Price Target Upside V Benchmarks

TypeNameUpside
StockMacroGenics41.51%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-11
Avg Price Target-$6.00$6.00
Last Closing Price$4.24$4.24$4.24
Upside/Downside-41.51%41.51%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
May, 26124--7
Apr, 26115--7
Mar, 26115--7
Feb, 26115--7
Jan, 26115--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Apr 20, 2026Barclays$6.00$3.4673.41%41.51%
May 14, 2025Peter LawsonBarclays$3.00$1.5988.68%-29.25%
Mar 25, 2025H.C. Wainwright$2.00$1.7911.73%-52.83%
Aug 07, 2024Stephen WilleyStifel Nicolaus$6.00$3.3877.51%41.51%
Jul 31, 2024Silvan TuerkcanJMP Securities$8.00$5.2552.38%88.68%
Jul 31, 2024Mayank MamtaniB.Riley Financial$5.00$5.25-4.76%17.92%
Jul 29, 2024Peter LawsonBarclays$9.00$5.5562.16%112.26%
May 23, 2024Kaveri PohlmanBTIG$9.00$4.6394.38%112.26%
May 13, 2024Debjit ChattopadhyayH.C. Wainwright$4.00$4.38-8.68%-5.66%
May 10, 2024Peter LawsonBarclays$14.00$14.67-4.57%230.19%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Apr 20, 2026BarclaysOverweightOverweighthold
Apr 10, 2026B. RileyNeutralBuyupgrade
Feb 24, 2026CitigroupMarket PerformMarket Performhold
May 14, 2025BarclaysOverweightOverweighthold
Sep 18, 2024JMP SecuritiesMarket PerformMarket Performhold
Sep 18, 2024H.C. WainwrightNeutralNeutralhold
Sep 16, 2024Cowen & Co.HoldHoldhold
Aug 21, 2024H.C. WainwrightNeutralNeutralhold
Aug 15, 2024JMP SecuritiesMarket PerformMarket Performhold
Jul 31, 2024BTIGBuyNeutraldowngrade

Financial Forecast

EPS Forecast

$-6 $-5 $-4 $-3 $-2 $-1 $0 $1 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-3.18$-1.95$-0.15$-1.07$-1.18---
Avg Forecast$-3.25$-2.03$0.43$-1.20$-2.20$-1.87$-2.31$-2.32
High Forecast$-1.59$-0.80$0.49$-1.02$-0.48$-0.55$-1.70$-0.16
Low Forecast$-5.05$-3.38$0.29$-1.40$-3.47$-3.30$-2.92$-5.50
Surprise %-2.15%-3.94%-134.88%-10.83%-46.36%---

Revenue Forecast

$0 $50M $100M $150M $200M $250M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$75.64M$150.02M$57.19M$148.34M$149.50M---
Avg Forecast$83.89M$150.06M$80.88M$159.93M$77.97M$87.38M$76.42M$120.09M
High Forecast$119.63M$226.35M$92.31M$172.05M$131.38M$88.48M$156.83M$246.44M
Low Forecast$50.95M$79.99M$68.52M$144.41M$18.14M$86.27M$21.65M$34.02M
Surprise %-9.83%-0.03%-29.29%-7.25%91.73%---

Net Income Forecast

$-350M $-260M $-170M $-80M $10M $100M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-202.12M$-119.76M$-9.06M$-66.97M$-74.62M---
Avg Forecast$-145.85M$-195.63M$49.82M$-74.81M$-176.54M$-164.31M$-143.21M$-143.88M
High Forecast$-116.68M$-156.51M$59.78M$-62.92M$-29.78M$-34.34M$-105.55M$-9.83M
Low Forecast$-175.02M$-234.76M$39.85M$-86.70M$-215.05M$-204.28M$-180.87M$-340.67M
Surprise %38.58%-38.78%-118.18%-10.49%-57.73%---

MGNX Forecast FAQ

Is MacroGenics stock a buy?

MacroGenics stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 12 Buy, 9 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that MacroGenics is a favorable investment for most analysts.

What is MacroGenics's price target?

MacroGenics's price target, set by 22 Wall Street analysts, averages $6 over the next 12 months. The price target range spans from $6 at the low end to $6 at the high end, suggesting a potential 41.51% change from the previous closing price of $4.24.

How does MacroGenics stock forecast compare to its benchmarks?

MacroGenics's stock forecast shows a 41.51% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for MacroGenics over the past three months?

  • May 2026: 14.29% Strong Buy, 28.57% Buy, 57.14% Hold, 0% Sell, 0% Strong Sell.
  • April 2026: 14.29% Strong Buy, 14.29% Buy, 71.43% Hold, 0% Sell, 0% Strong Sell.
  • March 2026: 14.29% Strong Buy, 14.29% Buy, 71.43% Hold, 0% Sell, 0% Strong Sell.

What is MacroGenics’s EPS forecast?

MacroGenics's average annual EPS forecast for its fiscal year ending in December 2026 is $-1.87, marking a 58.47% increase from the reported $-1.18 in 2025. Estimates for the following years are $-2.31 in 2027, and $-2.32 in 2028.

What is MacroGenics’s revenue forecast?

MacroGenics's average annual revenue forecast for its fiscal year ending in December 2026 is $87.38M, reflecting a -41.55% decrease from the reported $149.5M in 2025. The forecast for 2027 is $76.42M, and $120.09M for 2028.

What is MacroGenics’s net income forecast?

MacroGenics's net income forecast for the fiscal year ending in December 2026 stands at $-164M, representing an 120.20% increase from the reported $-74.62M in 2025. Projections indicate $-143M in 2027, and $-144M in 2028.